Abstract
In this review, we discuss the γ-secretase protease complexes, which are responsible for the generation of amyloid-β peptides that constitutes the amyloid plaques of Alzheimers disease (AD). We begin with a brief review on the amyloid-β precursor protein (APP), its proteolytic cleavage and a brief discussion on the pathogenesis of AD. We then present the four major components of the γ-secretase complexes - presenilin, nicastrin, Aph-1, and Pen-2 and also introduce the importance of post-translational modification activity of the γ-secretase complexes. We then discuss the diversity of γ-secretase substrates and proposed biological functions. Next we review the current therapeutic strategies aimed at developing selective inhibitors of AD-associated γ-secretase activities. Finally, we present a discussion, which serves as a platform for further questions into the viability of γ-secretase as an AD therapeutic target.
Keywords: Alzheimer's disease, Amyloid-beta (Aβ), gamma-secretase, presenilin, regulated intramembrane proteolysis, posttranslational modification
Current Signal Transduction Therapy
Title: Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Volume: 5 Issue: 2
Author(s): Run Yan and Justin V. McCarthy
Affiliation:
Keywords: Alzheimer's disease, Amyloid-beta (Aβ), gamma-secretase, presenilin, regulated intramembrane proteolysis, posttranslational modification
Abstract: In this review, we discuss the γ-secretase protease complexes, which are responsible for the generation of amyloid-β peptides that constitutes the amyloid plaques of Alzheimers disease (AD). We begin with a brief review on the amyloid-β precursor protein (APP), its proteolytic cleavage and a brief discussion on the pathogenesis of AD. We then present the four major components of the γ-secretase complexes - presenilin, nicastrin, Aph-1, and Pen-2 and also introduce the importance of post-translational modification activity of the γ-secretase complexes. We then discuss the diversity of γ-secretase substrates and proposed biological functions. Next we review the current therapeutic strategies aimed at developing selective inhibitors of AD-associated γ-secretase activities. Finally, we present a discussion, which serves as a platform for further questions into the viability of γ-secretase as an AD therapeutic target.
Export Options
About this article
Cite this article as:
Yan Run and V. McCarthy Justin, Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112217
DOI https://dx.doi.org/10.2174/157436210791112217 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Meet Our Editorial Board Member
Current Cancer Therapy Reviews Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Telomeric G-Quadruplex Architecture and Interactions with Potential Drugs
Current Pharmaceutical Design MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Emerging Facts on Chronic Consumption of Aspartame as Food Additive
Current Nutrition & Food Science O-6-methylguanine-DNA Methyltransferase Inhibits Gastric Carcinoma Cell Migration and Invasion by Downregulation of Matrix Metalloproteinase 2
Anti-Cancer Agents in Medicinal Chemistry